Meta-analysis of patients with resolved HBV on rituximab without antiviral prophylaxis: reactivation was 27.3% with negative anti-HBs, 13.8% with titre <100 iU/L and 3.5% with titre >100 iU/L (overall 12.6%).
Meta-analysis
Poola et al. Meta-Analysis: High anti-HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment